Inititates multiple ascending dose studies
Suven Life Sciences announced that it has completed the single ascending dose (SAD) studies of SUVN-G3031 in healthy human volunteers and initiated multiple ascending dose studies (MAD) as a part of the Phase I study currently ongoing in USA under US-IND 123179.SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the treatment of cognitive dysfunction associated with Alzheimer's disease and Schizophrenia.
Powered by Capital Market - Live News